Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6733425 | 0.89 | CYP1A2 (0.32) | BTK | |
| SCHEMBL3149019 | 0.86 | CYP1A2 (0.32) | EPHX1 | |
| SCHEMBL3147169 | 0.84 | CYP1A2 (0.37) | — | |
| SCHEMBL3165427 | 0.84 | CYP1A2 (0.37) | — | |
| SCHEMBL3258056 | 0.84 | CYP1A2 (0.37) | — | |
| SCHEMBL13451214 | 0.81 | CYP1A2 (0.37) | EPHX2 | |
| SCHEMBL3151613 | 0.81 | CYP1A2 (0.37) | EPHX2 | |
| SCHEMBL13450807 | 0.76 | — | — | |
| SCHEMBL13451155 | 0.76 | — | — | |
| SCHEMBL8347018 | 0.74 | HPGD (0.39) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379494-B1 | FUSED BICYCLIC OR TRICYCLIC AMINO ACIDS | WARNER LAMBERT CO (US) | 2010-03-10 | — | — | EP | disclosed |
| US-20040092591-A1 | Therapeutic use of fused bicyclic or tricyclic amino acids | BLAKEMORE DAVID CLIVE (GB) | 2004-05-13 | — | — | US | disclosed |
| US-20030078300-A1 | Fused bicyclic or tricyclic amino acids | PFIZER INC. | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078300-A1 | Fused bicyclic or tricyclic amino acids | AADAT, SLC1A2, BCAT1 | EPHX2 1685/4885BTK 3398/4885EPHX1 2158/4885 |
| US-20040092591-A1 | Therapeutic use of fused bicyclic or tricyclic amino acids | BCAT1, BCAT2, AADAT | EPHX2 2575/4885BTK 2264/4885EPHX1 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.